Adjuvant Fractionated Stereotactic Radiosurgery Outperforms Single-Fraction Treatment in Resected Brain Metastases
When a typical patient with a larger brain metastasis undergoes surgical resection, adjuvant fractionated stereotactic radiosurgery should replace single-fraction stereotactic radiosurgery as the clinical standard of care, according to findings from the Alliance A071801 phase 3 clinical trial presented on Cancer Network. The trial results demonstrated significantly better local control in the surgical bed without an apparent increase in patient toxicity.
Principal investigators evaluated outcomes for patients enrolled with brain metastases exceeding 2 centimeters in size. Historically, single-fraction stereotactic radiosurgery (SRS) served as the default radiation approach following the removal of a brain tumor. Trial data now indicate that extending radiation delivery across multiple fractions offers superior disease control at the surgical site for this patient population.
Evaluating Toxicity and Radiation Necrosis Rates
Crude rates of radiation necrosis remained comparable between the two trial arms during initial evaluations. Approximately 10% to 15% of patients in both the single-fraction and fractionated stereotactic radiosurgery cohorts experienced radiation necrosis. Investigators noted that while final time-to-event analyses are pending completion in the coming weeks, preliminary data revealed no meaningful differences in toxicity risks between the treatment schedules.
Local recurrences following single-fraction or fractionated SRS present significant clinical management challenges. Distinguishing a true tumor recurrence from radiation necrosis often requires additional diagnostic testing and patient monitoring. Uncontrolled local recurrence frequently necessitates secondary neurosurgical resection, which carries its own set of procedural complications.
Patient Counseling and Treatment Protocols
Radiation oncologists are adjusting preoperative and postoperative counseling discussions to reflect the trial findings. Clinicians now advise patients that extending radiation therapy from a single day to a span of three to five days helps prevent local tumor recurrence in the surgical cavity. While this protocol requires two to four additional hospital visits, multidisciplinary teams emphasize that reducing the downstream morbidity of recurrent disease justifies the extended schedule.
Single-fraction SRS maintains a clinical role in specific scenarios. Patients with smaller brain metastases or those with a severely limited extracranial prognosis often prefer a single treatment session over a multi-day protocol. Clinicians tailor these decisions through direct coordination with neurosurgery, balancing patient preferences, caregiver logistics, and individual disease parameters.
Researchers are also examining whether fractionation benefits patients with intact, unresected brain metastases. Although a phase 3 NRG study (NCT06500455) has completed accrual with results pending, preliminary analyses from the current trial showed an encouraging trend toward improved local control with fractionated SRS in unresected tumors, yielding a P value of .06.
Frequently Asked Questions
What specific trial demonstrated these findings?
The findings stem from the Alliance A071801 phase 3 clinical trial, which evaluated postoperative single-fraction stereotactic radiosurgery versus fractionated stereotactic radiosurgery for resected brain metastasis.
What size criteria were required for patients entering the trial?
Patients enrolled in the study were required to have a brain metastasis measuring over 2 centimeters in size.
What is the upcoming research focus regarding preoperative versus postoperative radiation?
Ongoing clinical trials are investigating whether preoperative stereotactic radiation offers a superior paradigm compared to postoperative SRS by minimizing meningeal seeding and reducing radiation necrosis.
Related reading